NCT00696878View on ClinicalTrials.gov

Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)

PHASE3CompletedINTERVENTIONAL
Enrollment

682

Participants

Timeline

Start Date

September 26, 2006

Primary Completion Date

February 17, 2009

Study Completion Date

May 15, 2009

Conditions
In Vitro Fertilization
Interventions
DRUG

Corifollitropin alfa

Corifollitropin alfa 150 µg administered as a single subcutaneous dose.

BIOLOGICAL

FSH

FSH administerd subcutaneously at a dose not to exceed 225 IU/day.

BIOLOGICAL

GnRH antagonist

GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.

BIOLOGICAL

(rec)hCG

(rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.

DRUG

Progesterone

Progesterone administered vaginally at a dose of at least 600 mg/day.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00696878 - Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714) | Biotech Hunter | Biotech Hunter